Migraines » Blog Archive » Alexza Pharmaceuticals To Present AZ-001 Phase IIb Clinical Data At The American Headache Society Meeting

Categories

Add to Technorati Favorites

Recent Posts

Telcagepant Proven As A Safe And Effective Migraine Treatment In Phase III Trial
Patent Foramen Ovale Closure Extremely Promising For Stroke Prevention And Treatment Of Migraine
Overuse Of Narcotics And Barbiturates May Make Migraine Worse
1 In 4 Gulf War Veterans Suffer From Illness Caused By Toxic Exposure
500-Patient Study Measuring Cognitive Processing Efficiency During Migraine Attacks
Breakthrough’s Comment On Research Suggesting Women Who Have Migraines Have A Reduced Risk Of Breast Cancer
Pycnogenol Cut Jetlag Symptoms In Half For Passengers Taking 7- To 9-hour Flights
Women Who Have Migraines Have Lower Breast Cancer Risk
Doctors Stress Pressing Need For Research Into The Best Treatment For Medication Overuse Headaches
Minster Pharmaceuticals Plc Announces Positive Results From Phase II Trial Of Migraine With Aura

Blogroll

Medical Links

Aches And Pains

Alexza Pharmaceuticals To Present AZ-001 Phase IIb Clinical Data At The American Headache Society Meeting

July 29th, 2007 by admin

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will present at the 49th Annual American Headache Society Meeting the results of a Phase IIb clinical trial of Staccato(R) prochlorperazine (AZ-001) for the acute treatment of migraine headache. [click link for full article]

More: continued here

Posted in treatment for migraine headaches |

Leave a Comment